Levio Sherry, Cash Brooks D
Division of Gastroenterology, University of South Alabama, Mobile, AL, USA.
Division of Gastroenterology, University of South Alabama, 6000 University Commons, 75 University Boulevard South, Mobile, AL 36688, USA.
Therap Adv Gastroenterol. 2017 Sep;10(9):715-725. doi: 10.1177/1756283X17721152. Epub 2017 Jul 24.
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Among individuals with IBS, the condition has dramatic effects on health-related quality of life, work and school productivity, and activities of daily living. It may be diagnosed with confidence, based on symptom-based diagnostic criteria, exclusion of alarm features and directed diagnostic testing. Management of IBS typically begins with dietary and lifestyle modifications, progressing to over-the-counter therapies, and then to prescription medications, both approved and nonapproved for IBS. This narrative summarizes the efficacy and safety of three US Food and Drug Administration (FDA)-approved prescription therapies for IBS with diarrhea (IBS-D), with a focus on the most recently marketed agent, eluxadoline, and its role in the treatment IBS-D.
肠易激综合征（IBS）是一种常见的功能性胃肠疾病，其特征为与排便相关的腹痛，伴有大便频率或大便形态改变。IBS的全球患病率在10%至15%之间，IBS导致的总医疗费用相当可观。在患有IBS的个体中，该疾病对健康相关生活质量、工作和学习效率以及日常生活活动有显著影响。基于症状诊断标准、排除警示特征和针对性诊断测试，可确诊IBS。IBS的治疗通常始于饮食和生活方式的调整，接着是使用非处方疗法，然后是使用已批准和未批准用于IBS的处方药。本叙述总结了三种美国食品药品监督管理局（FDA）批准的治疗腹泻型肠易激综合征（IBS-D）的处方疗法的疗效和安全性，重点介绍了最新上市的药物eluxadoline及其在治疗IBS-D中的作用。
